Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial
Avexa Limited (ASX:AVX) announced that the Data Safety Monitoring Board (DSMB) met today to review the 16 week data from Avexa"s apricitabine (ATC) Phase III clinical trial. The DSMB reviewed the data and recommended continuation of the study with the 800mg dose. Patients taking the 1200mg dose will be transitioned to the optimum 800mg dose to continue their therapy.

Opinion Pieces, Editorials Comment On Obama's Notre Dame Commencement Speech
Several newspapers recently published opinion pieces and editorials regarding President Obama"s commencement address at the University of Notre Dame on Sunday. Summaries appear below.~ Austin Hill, U.S. News and World Report: A "careful look" at the controversy surrounding Notre Dame"s invitation to Obama "suggests that ... the Catholic Church in America is neither communicating very clearly to the broader American society, nor is it communicating very clearly among its own members," columnist Hill writes. Hill asks, "[I]f Catholics need to criticize a political figure even when he is "right" on the abortion issue, can they, or should they, praise a political figure even when he is "wrong" on the abortion issue" but "right" on other moral issues? He adds, "The bishops need to answer this question, in no uncertain terms, and they need to do so with clarity" (Hill, U.S. News and World Report, 5/20).~ William Saletan, Slate: Abortion is "the classic multidimensional issue," and "Obama"s acknowledgment of the issue"s complexity is important for two reasons," author and Slate correspondent Saletan writes. The first reason is that Obama is "dropping the pretense of a conclusive answer," and the second is that "even strategic symbolic dialogue can bring unforeseen consequences," Saletan writes (Saletan, Slate, 5/20).~ Julia Duin, Washington Times: A number of things "did not seem right" about Obama"s speech,"[e]specially about "common ground" on an issue that has none" -- abortion rights, columnist Duin writes. Duin asks, "Does this "common ground" idea really work? On peripheral issues, yes. On life-and-death issues, no." According to Duin, "It seems that one side of the debate is always told it needs to move to the center on a given issue, while the other side is told it needs to stand firm." She adds that Obama"s speech highlighted "a huge disconnect," possibly "that some issues don"t have a common ground" (Duin, Washington Times, 5/21).~ Marybeth Hicks, Washington Times: In his speech, Obama "shared a world view that people of all strongly held beliefs must consider: While we will never agree on certain matters of principle, we should still find ways to lift up mankind through cooperation and service and love," columnist Hicks writes. Hicks says that she would like "Obama to send a copy of that speech to Harry Knox" -- director of the religion and faith program at the Human Rights Campaign and a member of Obama"s White House Council on Faith-based and Neighborhood Partnerships -- because Knox "must learn to respect the right of Catholics and of our church to hold principled beliefs of our own" (Hicks, Washington Times, 5/20).~ Dallas Morning News: Obama "[o]nce again ... displayed his gift for making his most strident opponents marginalize themselves" by "com[ing] across as the kind of politician who genuinely sees those who disagree with him as opponents, not enemies," a Morning News editorial says. "When a strong abortion-rights supporter like Obama is not only honored at the nation"s most important Catholic university (in terms of cultural symbolism), but enthusiastically embraced, times are changing," it adds (Dallas Morning News, 5/18).~ Kansas City Star: Most Americans "have more in common with the 12,000 graduates, families and friends who were inside the Notre Dame arena than with the demonstrators outside" and "are willing to listen to different views and ... seek a middle ground that would lessen the [abortion] issue"s grip on political discourse," a Star editorial states. It continues, "Instead of ostracizing those of different views, Americans would do better to follow the path suggested by Obama: Reduce unintended pregnancies, make adoption more available and provide "care and support for women who do carry their children to term"" (Kansas City Star, 5/18).~ Baltimore Sun: Obama "met the challenge head-on" of speaking at Notre Dame amid the protests through "his faith in the ability of reasonable people to disagree and still find common gro
News of the day
PM&R Accepted For Abstracting And Indexing In MEDLINE
Elsevier, a world-leading publisher of scientific, technical and medical information products and services, is pleased to announce that PM&R - The journal of injury, function and rehabilitation, the official scientific journal of the American Academy of Physical Medicine and Rehabilitation (AAPM&R), has been accepted for coverage by MEDLINE, just six months after its launch in January 2009.
Health Insurance

Reducing Drug Side-Effects In Pain Relief: New Research

They are a group of drugs which millions of people rely on to keep pain at bay but they can have unwanted side-effects which are sometimes more serious than the original health problem. Now scientists at The University of Nottingham are taking part in the largest-ever study on the safety of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) that has ever been performed. The project is called SOS (Safety Of non-Steroidal anti-inflammatory drugs) and will study the medical information of 35 million people in Europe to assess the incidence and nature of harmful side-effects on the cardiovascular and gastrointestinal systems of patients. It"s hoped the results will lead to better guidance for doctors on how to balance the advantages of prescribing the drugs with the associated risks of heart and digestive problems. NSAIDS are widely used in medicine for treating pain, inflammation and degenerative diseases like arthritis. The most commonly-used are aspirin and ibuprofen. But their use is associated with an increased risk of minor and serious gastrointestinal complications. It"s estimated that there are thousands of these cases in the European Union every year. Prompted by these problems, a new class of NSAIDS called "Coxibs" have been developed to reduce the risk of this type of side-effect, but the use of these new drugs has since been linked with an increased risk of heart problems such as heart attack and stroke. Clinicians and scientists now agree that the risk of stomach problems has to be balanced against the risk of cardiovascular interference. Both risks may differ in one person and for the 30 different types of NSAIDS available in the EU. Up to now research studies have been too small to be effective in terms of providing decision models for doctors and drug regulators but it"s hoped this new large survey will result in a much more accurate prescription method to minimize drug-related harm. Over the next two and a half years, published literature on previous clinical trials and observational studies will be scrutinized to identify any methodological inconsistencies and knowledge gaps and this information will be used to design and carry out an EU-wide observational study. This study will be the biggest of its kind ever undertaken in this field. It will include data from more than 35 million Europeans, taken from existing healthcare databases in the UK, the Netherlands, Germany and Italy. The researchers will use the data to create a variety of decision models to help doctors prescribe the most suitable type of NSAID for a particular patient and lower the risk of unwanted gastrointestinal or cardiovascular side-effects. The University of Nottingham is working with ten other leading European research institutions on the three-year project which is being funded with a 2.8 million Euros grant from the EC"s 7th Framework Programme. Fundamental to the project is QResearch, a not-for-profit partnership between The University of Nottingham and leading primary care system supplier EMIS, which uses data collected over the past 17 years. Professor of Clinical Epidemiology and General Practice, Julia Hippisley-Cox, who founded QResearch, said: "The SOS project will help quantify and compare the risks of different NSAIDs based on an individual"s profile and should help lead patients and doctors make better decisions regarding treatment options". Additional Information Project website: http://www.sos-nsaids-project.org Participating institutions: * Erasmus University Medical Centre, Netherlands * FundaciÃö IMIM, Spain * University of Nottingham, UK * Università di Milano-Bicocca, Italy * Research Triangle Institute, USA * Universitaet Bremen, Germany * The Research Institute of the McGill University Health Centre, Canada * Azienda Ospedaliera di Padova, Italy * PHARMO Cooperation UA, Netherlands * Université Victor-Segalen Bordeaux II, France * Azienda Sanitaria Locale della provincia di Cremona, Italy Professor Julia Hippisley-Cox University of Nottingham


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009